Materials and Methods: This retrospective study included 58 diabetic patients with diffuse DME. Bevacizumab group included 30 patients who received 3 doses intravitreal bevacizumab (1.25 mg/0.05 ml) for DME. Ranibizumab group included 28 patients who received 3 doses intravitreal ranibizumab (0.5 mg/0.05 ml) for DME. Baseline best corrected visual acuity (BCVA), intraocular pressure (IOP), central macular thickness (CMT) and retinal examination with +78 diopters lens, were performed and repeated at 1st, 2nd, and 3rd month after injections in all patients. BCVA, CMT, and IOP for baseline and after treatment were compared in both groups.

Results: Mean age of patients was 59.97±9.48 years, diabetes duration was 10.5±7.27 years in the bevacizumab group. Mean age was 61.04±8.15 years, diabetes duration was 10.61±8.35 years in the ranibizumab group. Follow up time was 4.0±0.1 months. Baseline BCVA (in snellen) was 0.32 decimal (0.50 log MAR)in the bevacizumab group and 0.31 decimal (0.51 logMAR)in the ranibizumab group (p=0.82). Improvement in BCVA was significant in both groups (p<0.001). Baseline CMT was 394±93 μm in the bevacizumab group and 384±96 μm (p=0.71) in the ranibizumab group. Decrease in CMT was significant after intravitreal injection.

Conclusion: Significant improvement in BCVA and CMT were observed after treatment with bevacizumab and ranibizumab injection with no significiant difference between groups at the short term. Keywords : Bevacizumab, central macular thickness, diabetic macular edema, ranibizumab